Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV – Medscape

Written by

admin

in

  1. Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV  Medscape
  2. 52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV  AJMC
  3. Takeda (TAK): Promising Results for Rusfertide in Phase 3 VERIFY Study  GuruFocus
  4. Rusfertide Maintains Hematocrit Control Through 52 Weeks in VERIFY  HCPLive
  5. Rusfertide Continues to Show Strong Results for Polycythemia Vera  OncLive

Continue Reading

More posts